Advances in Hodgkin lymphoma: A Theme Issue in Honor of Prof. Dr. Harald Stein

A special issue of Hemato (ISSN 2673-6357). This special issue belongs to the section "Lymphomas".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 2828

Special Issue Editors


E-Mail Website
Guest Editor
Professor of Pathology, Former Chairman of Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Aviano, Italy
Interests: hematopathology; Hodgkin lymphoma; non Hodgkin lymphoma; HIV-associated lymphoma; virus-associated lymphoma; post-transplant lymphoma; pathology; immunohistochemistry; tumour microenvironment; telepathology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Hematology and Clinical Immunology, Centro di Ricerche Emato-Oncologiche (CREO), University of Perugia, Perugia, Italy
Interests: hematopathology; hematology; Immunology

E-Mail Website
Guest Editor
Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy
Interests: haematopathology; immunology and molecular pathology of B-cell lymphomas
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are preparing a Special Issue in honor of Prof. Harald Stein because of his important contribution to the modern classification of lymphomas.

When Harald Stein was employed in Karl Lennert’s Institute in 1968, he was exposed to Lennert’s classification. Stein could not understand the doctrine of the classification that large cell neoplasms of lymph nodes are derived from reticulum cells. This doctrine was based on morphology alone. Nobody at the time knew what reticulum cells were, and the reproducibility of the diagnosis was low. Therefore, Stein decided to search for molecular markers. In 1970, Stein read the Nature publication by Martin Raff in which Raff reported that B cells carry IgM on their surface. Stein then analyzed reticulum sarcomas for IgM with the radial immunodiffusion technique. The majority of these tumors were IgM positive, and thus, proved to be B-cell lymphomas (Stein et al. Lancet 2002). However, it took Stein 9 years to solve the classification of IgM-negative large cell tumors. Stein and his team of Johannes Gerdes and Hilmar Lemke succeeded in 1981 when they discovered—by using the L428 cell line—the Ki-1 molecule; in 1986, this was included in the CD classification as CD30. The  IgM-negative large cell tumors proved to be Ki-1/CD30 positive and were first called Ki-1 lymphomas; they were finally designated, on Stein’s proposal, as anaplastic large cell lymphomas (ALCL). For the worldwide application of CD30 for diagnostic purposes, Stein generated with another team the monoclonal antibody Ber-H2 which functions on FFPE tissue sections (1989). The usage of Ber-H2 (Ber for Berlin) confirmed the constant expression of CD30 by HRS cells of classical Hodgkin lymphoma (CHL) and its constant absence in lymphocyte-predominant Hodgkin lymphoma (NLPHL).  The application of the Ber-H2 antibody was further revealed by the large European Task Force on Lymphoma project to be a new subtype of CHL: nodular lymphocyte-rich classical Hodgkin lymphoma (NLRCHL), which was frequently misdiagnosed as NLPHL. Stein also discovered with Johannes Gerdes and Hilmar Lemke the Ki-67 molecule as a marker for cell proliferation, which was published in 1983.

In cooperation with David Mason, Stein generated monoclonal antibodies specific for B cells (clustered as CD22) and follicular dendritic cells (clustered das CD21).

In 1991, Stein and Peter Isaacson founded the “International Lymphoma Study Group (ILSG)” by bringing together 19 internationally known experts in hematopathology with the aim of establishing a biologically correct lymphoma classification valid on both sides of the Atlantic. In 1994, the ILSG proposed the REAL classification of lymphomas, which was subsequently taken over by the WHO classification. Stein worked as a co-editor for the WHO’s lymphoma projects until 2017.

Prof. Dr. Antonino Carbone
Prof. Dr. ‪Brunangelo ‪Falini
Prof. Dr. Lorenzo Leoncini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hodgkin lymphoma

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 1792 KiB  
Review
Mediastinal Gray-Zone Lymphoma: Still an Open Issue
by Stefano Pileri, Valentina Tabanelli, Roberto Chiarle, Angelica Calleri, Federica Melle, Giovanna Motta, Maria Rosaria Sapienza, Elena Sabattini, Pier Luigi Zinzani and Enrico Derenzini
Hemato 2023, 4(3), 196-206; https://doi.org/10.3390/hemato4030016 - 27 Jun 2023
Viewed by 2197
Abstract
The concept of gray-zone lymphoma (GZL) has been progressively refined since its introduction in the literature in 1998. For several years, it was applied to a rather broad spectrum of conditions, posing the problem of the differential diagnosis between any type of Hodgkin [...] Read more.
The concept of gray-zone lymphoma (GZL) has been progressively refined since its introduction in the literature in 1998. For several years, it was applied to a rather broad spectrum of conditions, posing the problem of the differential diagnosis between any type of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma, with special reference to primary mediastinal forms (PMBL). Officially recognised as a provisional entity in the 4th and revised 4th editions of the WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues with the term “B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma”, it was limited to tumours showing either morphologic features reminiscent of classic HL (CHL) but carrying a complete B-cell phenotype or conversely provided with a PMBL morphology yet revealing CHL phenotypic characteristics. The definition of GZL has been further revised in the recently published International Lymphoma Classification and 5th edition of the WHO Classification of Haematolymphoid Tumours, which have limited it to mediastinal neoplasms (MGZL) based on emerging molecular evidence. The aim of this review is to critically discuss the issue of MGZL, as well as in light of the suboptimal response to current therapies. Full article
Show Figures

Figure 1

Back to TopTop